coelenterazine and Peripheral-Nerve-Injuries

Functional recovery after peripheral nerve injury (PNI) is poor, mainly due to the slow and incomplete regeneration of injured axons. Experimental therapies that increase the excitability of the injured axons have proven remarkably successful in promoting regeneration, but their clinical applicability has been limited. Bioluminescent optogenetics (BL-OG) uses luminopsins, fusion proteins of light-generating luciferase and light-sensing ion channels that could be used to increase neuronal excitability if exposed to a suitable substrate. Excitatory luminopsins were expressed in motoneurons of transgenic mice and in wildtype mice transduced with adeno-associated viral vectors. Intraperitoneal administration of coelenterazine (CTZ), a known luciferase substrate, generated intense bioluminescence in peripheral axons. This bioluminescence increased motoneuron excitability. A single administration of CTZ immediately after sciatic nerve transection and repair markedly enhanced motor axon regeneration. Compound muscle action potentials were 3-4 times larger than controls by 4 weeks after injury. The results observed with transgenic mice were comparable to those of mice in which the luminopsin was expressed using viral vectors. Significantly more motoneurons had successfully reinnervated muscle targets four weeks after nerve injury in BL-OG treated mice than in controls. Bioluminescent optogenetics is a promising therapeutic approach to enhancing axon regeneration after PNI.

Topics: Animals; Axons; Disease Models, Animal; Evoked Potentials, Motor; Female; Humans; Imidazoles; Luminescent Agents; Luminescent Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Neurons; Nerve Regeneration; Optogenetics; Peripheral Nerve Injuries; Pyrazines; Recombinant Fusion Proteins; Regenerative Medicine

Topics: Animals; Evoked Potentials, Motor; Female; Imidazoles; Luciferases, Renilla; Luminescent Agents; Mice, Transgenic; Motor Activity; Motor Neurons; Nerve Regeneration; Optogenetics; Peripheral Nerve Injuries; Pyrazines; Recovery of Function; Sciatic Nerve